title: Virus-inhibiting factor in primary and metastatic carcinoma of the liver.
abstract: Sera from patients with hepatoma, metastatic liver disease, cirrhosis of the liver, and benign diseases of the digestive tract have been tested for a virus-inhibiting factor. Serum samples exerting complete inhibition of virus CPE in a dilution of at least 1:10 per 0.2 ml are considered positive, and those exerting 50% inhibition of CPE are regarded as weakly positive. An apparently positive antiviral activity was noted in the sera of patients with hepatoma (53.3%) and metastatic liver disease (46.6%). Patients with cirrhosis of the liver showed positivity in one of ten sera; no positive antiviral activity could be found in the sera of patients with benign diseases of the digestive tract. The percentage of weakly positive response was 33.3% and 13.3% for hepatoma and metastatic liver disease, respectively, and 10.0% for the benign diseases and 20.0% for the cirrhotic sera. The antiviral activity was more prominent in the embryonic foreskin fibroblasts and to a lesser degree in the bovine epithelial cells NBL-1.
mesh_terms: D000998:Antiviral Agents / Q000302:isolation & purification*; D006528:Carcinoma, Hepatocellular / Q000276:immunology*; D003588:Cytopathogenic Effect, Viral; D006801:Humans; D008103:Liver Cirrhosis / Q000276:immunology; D008113:Liver Neoplasms / Q000276:immunology* / Q000556:secondary
chemical_list: D000998:Antiviral Agents